Last reviewed · How we verify
Entecavir dispersible tablets
Inhibits hepatitis B virus DNA polymerase
Inhibits hepatitis B virus DNA polymerase Used for Chronic hepatitis B.
At a glance
| Generic name | Entecavir dispersible tablets |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | nucleoside analogue |
| Target | HBV DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Entecavir is a nucleoside analogue that selectively inhibits the replication of hepatitis B virus (HBV) by competing with the natural nucleoside substrate for the viral DNA polymerase.
Approved indications
- Chronic hepatitis B
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects (PHASE2)
- Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers (PHASE3)
- A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B (PHASE1, PHASE2)
- A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B (PHASE2)
- Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers (PHASE2)
- Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis (PHASE4)
- Optimized Treatment and Regression of HBV-induced Early Cirrhosis (PHASE4)
- Optimized Treatment and Regression of HBV-induced Liver Fibrosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: